CRBU Caribou Biosciences Inc
Price (delayed)
$0.7675
Market cap
$71.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
$81.58M
Highlights
Caribou Biosciences's debt has decreased by 2.3% YoY
CRBU's gross profit has plunged by 71% YoY and by 13% from the previous quarter
The revenue has dropped by 71% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of CRBU
Market
Valuations
Earnings
Shares outstanding
93M
Market cap
$71.38M
Enterprise value
$81.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
6.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.16
Revenue
$9.99M
Gross profit
$9.99M
Operating income
-$166.62M
Net income
-$149.11M
EBIT
-$149.11M
EBITDA
-$143.01M
Free cash flow
-$143.07M
Per share
Balance sheet
Liquidity
EPS
-$1.65
EPS diluted
-$1.65
Free cash flow per share
-$1.58
Book value per share
$2.79
Revenue per share
$0.11
TBVPS
$3.47
Total assets
$313.31M
Total liabilities
$60.36M
Debt
$26.49M
Equity
$252.95M
Working capital
$188.73M
Debt to equity
0.1
Current ratio
7.16
Quick ratio
6.9
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
-1,431%
Gross margin
100%
Net margin
-1,491.9%
Operating margin
-1,667.2%
Return on assets
-41.5%
Return on equity
-50.2%
Return on invested capital
-46.4%
Return on capital employed
-52.8%
Return on sales
-1,492%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBU stock price
How has the Caribou Biosciences stock price performed over time
Intraday
-2.23%
1 week
-18.27%
1 month
-30.23%
1 year
-83.09%
YTD
-51.73%
QTD
-15.95%
Financial performance
How have Caribou Biosciences's revenue and profit performed over time
Revenue
$9.99M
Gross profit
$9.99M
Operating income
-$166.62M
Net income
-$149.11M
Gross margin
100%
Net margin
-1,491.9%
CRBU's gross profit has plunged by 71% YoY and by 13% from the previous quarter
The revenue has dropped by 71% year-on-year and by 13% since the previous quarter
Caribou Biosciences's net income has decreased by 46% YoY
Caribou Biosciences's operating income has decreased by 44% YoY
Growth
What is Caribou Biosciences's growth rate over time
Valuation
What is Caribou Biosciences stock price valuation
P/E
N/A
P/B
0.27
P/S
6.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.16
Caribou Biosciences's EPS has decreased by 20% YoY
The P/B is 66% less than the last 4 quarters average of 0.8
The equity fell by 31% YoY and by 10% QoQ
The revenue has dropped by 71% year-on-year and by 13% since the previous quarter
CRBU's P/S is 42% below its last 4 quarters average of 12.0
Efficiency
How efficient is Caribou Biosciences business performance
The ROE has plunged by 61% YoY and by 10% from the previous quarter
CRBU's ROA has dropped by 61% year-on-year and by 9% since the previous quarter
CRBU's return on invested capital is down by 49% year-on-year and by 8% since the previous quarter
Caribou Biosciences's return on sales has decreased by 16% QoQ
Dividends
What is CRBU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBU.
Financial health
How did Caribou Biosciences financials performed over time
The quick ratio is down by 41% year-on-year and by 3.5% since the previous quarter
The current ratio has contracted by 40% YoY and by 3% from the previous quarter
Caribou Biosciences's debt is 90% less than its equity
Caribou Biosciences's debt to equity has increased by 43% YoY and by 11% from the previous quarter
The equity fell by 31% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.